Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B‐cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity

Dr. Reddy's Laboratories rituximab (DRL_RI; Dr. Reddy's Laboratories SA, Basel, Switzerland) is under development as a rituximab biosimilar. Study RI‐01‐002 (Clinical Trials Registry ‐ India/2012/11/003129), comparing DRL_RI to the reference medicinal product (RMP) MabThera® (Roche, Grenza...

Descripción completa

Detalles Bibliográficos
Autores principales: Svensson, Robin J., Ooi, Qing Xi, Friberg, Lena E., Maharaj, Narendra, Reddy, Pramod Kumar, López‐Lázaro, Luis, Hansson, Emma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931428/
https://www.ncbi.nlm.nih.gov/pubmed/36330695
http://dx.doi.org/10.1002/psp4.12885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931428/
https://www.ncbi.nlm.nih.gov/pubmed/36330695
http://dx.doi.org/10.1002/psp4.12885

Ejemplares similares